Alzheimer’s in the U.S.
Alzheimer’s 2100
Alzheimer’s drug marketSYMPTOM         PREVENTIVE                  0
Multiple attempts         Alzheimers Drug From Pfizer, J&J              Fails in Late-Stage Trial         Lilly Halts Alzh...
PREVENTIVE                      DRUG MARKET               $10B   $1BFAILED DRUGS
The best time to treat Alzheimer’sDisease is likely to be before memoryloss and tissue destruction occurs…
NORMAL BRAIN   ALZHEIMER’S
Alter the trajectory                     Current   disease        standard ofprogression         diagnosis                ...
Our technology                                   3   EYE         NEW     CHANGE      YEARSTRACKING      IMAGE   DETECTION ...
Alzheimer’s conversion    99.9%    of low scorers0                                      100                        0%     ...
Strategy  100 20,000                            1   new clinical    required           Phase IVtrials each year   patients...
the Alzheimer’s diagnostic
todayPatents filed   Worldwide       Pilotand pending      license     discussions
TeamElli Kaplan                    Colin McDonaldCEO                            CMO                   Scientific AdvisoryD...
Next stepsSeed capital                  Business                            development
Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)
Upcoming SlideShare
Loading in …5
×

Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)

1,199 views

Published on

Published in: Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,199
On SlideShare
0
From Embeds
0
Number of Embeds
343
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)

  1. 1. Alzheimer’s in the U.S.
  2. 2. Alzheimer’s 2100
  3. 3. Alzheimer’s drug marketSYMPTOM PREVENTIVE 0
  4. 4. Multiple attempts Alzheimers Drug From Pfizer, J&J Fails in Late-Stage Trial Lilly Halts Alzheimers Drug Trial Glaxo’s Avandia Fails to Benefit Alzheimer’s Patients
  5. 5. PREVENTIVE DRUG MARKET $10B $1BFAILED DRUGS
  6. 6. The best time to treat Alzheimer’sDisease is likely to be before memoryloss and tissue destruction occurs…
  7. 7. NORMAL BRAIN ALZHEIMER’S
  8. 8. Alter the trajectory Current disease standard ofprogression diagnosis Preventive time 3 years
  9. 9. Our technology 3 EYE NEW CHANGE YEARSTRACKING IMAGE DETECTION EARLIER
  10. 10. Alzheimer’s conversion 99.9% of low scorers0 100 0% of high scorers
  11. 11. Strategy 100 20,000 1 new clinical required Phase IVtrials each year patients approved therapy
  12. 12. the Alzheimer’s diagnostic
  13. 13. todayPatents filed Worldwide Pilotand pending license discussions
  14. 14. TeamElli Kaplan Colin McDonaldCEO CMO Scientific AdvisoryDr. Stuart ZolaDr. Beth BuffaloDr. Eugene Agichtein
  15. 15. Next stepsSeed capital Business development

×